A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

4-month study including a 30-day baseline phase

Completed

Looking for future studies?

Key information

Conditions

Postherpetic Neuralgia Nervous System Diseases Neuralgia Neuralgia, Postherpetic Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion criteria

Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Treatment and study plan

Botulinum Toxin Type A

Drug

Primary outcomes

Pain score

Secondary outcomes

Various Quality of Life questionnaires
Reduction in area of pain/allodynia

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Sep 15, 2005
Registry last updated: May 30, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed